Lixisenatide

DRUG11 trials

Sponsors

Novo Nordisk A/S, Lund University, University of Surrey, Medical University of Vienna, Profil Institut für Stoffwechselforschung GmbH

Conditions

DiabetesDiabetes After Total PancreatectomyDiabetes MellitusDiabetes Mellitus Type 2Diabetes Mellitus, Type 2Diabetic Kidney DiseaseDiabetic NephropathyGastroparesis

Phase 1

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

TerminatedNCT02231658

Profil Institut für Stoffwechselforschung GmbHDiabetes Mellitus

Start: 2015-07-16End: 2018-07-23Updated: 2018-10-17

Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

Royal Adelaide HospitalDiabetes Mellitus, Gastroparesis

Start: 2013-11-30End: 2016-04-30Target: 30Updated: 2015-10-29

Phase 2

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

CompletedNCT03439943

University Hospital, ToulouseParkinson Disease

Start: 2018-06-13End: 2021-04-15Updated: 2025-11-28

Phase 3

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

CompletedNCT02168491

Medical University of ViennaType 2 Diabetes Mellitus

Start: 2014-11-30End: 2015-08-31Updated: 2017-05-09

Phase 4

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

CompletedNCT01973231

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2013-10-31End: 2014-11-30Updated: 2017-02-09

Study on Lixisenatide and Counterregulation to Hypoglycemia

CompletedNCT02020629

Lund UniversityType 2 Diabetes

Start: 2013-12-31End: 2015-08-31Updated: 2015-12-15

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

CompletedNCT02049034

University of SurreyType 2 Diabetes

Start: 2014-01-31End: 2016-01-31Updated: 2024-12-16

Effect of LIXIsenatide on the Renal System

CompletedNCT02276196

Amsterdam UMC, location VUmcDiabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy +1

Start: 2014-09-30End: 2016-04-30Updated: 2016-04-29

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

TerminatedNCT02767596

Laniado HospitalDiabetes Mellitus Type 2

Start: 2016-07-12End: 2017-02-21Updated: 2017-04-07

Unknown Phase

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

CompletedNCT02640118

University Hospital, Gentofte, CopenhagenDiabetes After Total Pancreatectomy

Start: 2015-08-31End: 2016-07-31Updated: 2020-05-07

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

CompletedNCT02745470

Seoul National University HospitalDiabetes Mellitus

Start: 2016-02-29End: 2016-12-31Updated: 2017-11-29

Related Papers

Trial of Lixisenatide in Early Parkinson’s Disease

New England Journal of Medicine2024-04-03256 citations

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying

Diabetes Therapy2022-04-228 citations

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.

2020-05-1115 citations

Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.

2017-06-1617 citations

Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial

Diabetes Obesity and Metabolism2017-04-2761 citations

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.

2017-03-292 citations

Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.

2017-02-2317 citations

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

2017-02-2114 citations